Pharmaceutical Vaccines Is The Largest Segment Driving Growth Of...

Pharmaceutical Vaccines Is The Largest Segment Driving Growth Of The Intramuscular Vaccine Adjuvants Market

نشر بتاريخ 2023-11-27 10:35:25

2كيلو بايت

The global Intramuscular Vaccine Adjuvants Market is estimated to be valued at US$ 694.19 Mn or Million in 2023 and is expected to exhibit a CAGR of 6.7% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Intramuscular vaccine adjuvants are substances that are added to vaccines to enhance the immune response of vaccines. They help create a stronger and longer-lasting immunity against infections and diseases. Adjuvants allow for lower vaccine doses and offer broader protection.

Market key trends:
One of the key trends in the intramuscular vaccine adjuvants market is the increasing research and development of adjuvant systems. Adjuvants help improve the efficacy of vaccines and enhance the immune response. Researchers are developing novel adjuvant formulations that can be added to existing and new vaccines to boost their immunogenicity. This includes oil-in-water emulsion-based adjuvants, particulate-based adjuvants, immunostimulating complexes (ISCOMs), and others. Development of improved adjuvant systems will support the growth of the intramuscular vaccine adjuvants market.
Market key trends:
One of the key trends in the Global Intramuscular Vaccine Adjuvants Market is the growing adoption of carbohydrate adjuvants. Carbohydrate adjuvants are known to induce Th1-biased antigen-specific antibody and cellular immune responses when used as vaccine adjuvants. The high efficacy and safety profile of carbohydrate adjuvants have increased their adoption over the past few years. With the availability of novel carbohydrate adjuvant formulations, the demand for carbohydrate adjuvants is expected to rise significantly during the forecast period.

SWOT Analysis
Strength: Carbohydrate adjuvants offer high efficacy and safety. Growing focus on vaccine development against infectious diseases.
Weakness: Stringent regulatory norms associated with vaccine development. High R&D costs involved.
Opportunity: Rising prevalence of infectious diseases and cancer worldwide. Increasing government support for vaccine development.
Threats: Threat from alternative vaccine adjuvants. Patent expiries of major adjuvant brands.

Key Takeaways
The global intramuscular vaccine adjuvants market size was valued at US$ 694.19 Mn in 2023 and is expected to reach over US$ 1,300 Mn by 2030, expanding at a CAGR of 6.7% during the forecast period. The market is primarily driven by the rising prevalence of infectious diseases and increasing vaccination programs worldwide.

The Asia Pacific region dominated the global market in 2023 and is expected to witness the fastest growth during the forecast period. Rapidly improving healthcare infrastructure and increasing healthcare expenditure in emerging economies such as China and India are supporting the growth of the intramuscular vaccine adjuvants market in Asia Pacific.

Key players operating in the intramuscular vaccine adjuvants market are Novavax, Inc., Adjuvance Technologies, Inc., Invivogen, Vaxine Pty Ltd., SEPPIC, SPI Pharma, Inc., Agenus Inc., Avanti Polar Lipids, Inc., CSL Limited, and OZ Biosciences. The players are increasingly adopting collaboration and partnership strategies to develop novel adjuvant formulations and strengthen their market position.